Review of recent trials of chemotherapy for advanced breast cancer: Studies excluding taxanes

European Journal of Cancer

Volumn 33, Issue 13, 1997, Pages 2171-2182

  Demons, M ^a   Leahy, M ^a   Valle, J ^a   Jayson, G ^a   Ranson, M ^a   Hayes, S ^a   Howell, A ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; LONIDAMINE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; PIRARUBICIN; TAMOXIFEN; TEGAFUR; THIOTEPA; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0031426358     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00262-1     Document Type: Article

References (183)

1. Langer CJ, Catalane R, Weiner LM, et al. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced, measurable carcinoma. Cancer Invest 1995, 13, ISO-159.
2. O'Brien MER, Bonnefoi H, Seymour M, et cd. Infusional 5-fluorouracil with epirubicin and carboplatin in advanced metastatic breast cancer-can carbo replace cisplatin? Eur J Cancer 1995, 31A(Suppl. 5), 580.
3. Bonnefoi H, Smith IE, O'Brien ME, et al. Phase II study of continuous infusional 5-FU with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional E Carbo F): a very active and well tolerated out patient regimen. Br J Cancer 1996, 73, 391-396.
4. Bonnefoi H, Smith IE, O'Brien MER, et al. Phase II study of continuous infusional 5-FU with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer. A very active and well-tolerated out-patient regimen. BrJ Cancer 1996, 73, 391-396.
5. Closon M, Verbeke L, Kains J, et al. Combination chemotherapy with carboplatin, cyclophosphamide and fluorouracil in advanced breast cancer. Anticancer Res 1995, IS, 591-595.
6. Raymond E, Palangie T, Jouve M, et al. Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine and oral cyclophosphamide in advanced breast cancer. Cancer Invest 1996, 14, 91-97.
7. Zambetti M, Giacobone A, Terenziani M, et al. Sequential treatment with Adriamycin-CMF in metastatic breast cancer. ProcASCO 1995, 14, Abs163.
8. Levi JA, Beith JM, Snyder RD, et al. Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer. Aust NZJMed 1995, 25, 474-478.
9. laffaioli RV, Tortoriello A, Facchini G, et al. Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. Br Cancer Treat Res 1995, 35, 243-248.
10. Callari A, Gebbia V, Testa V, et al. A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma. Acta Oncol 1994, 33, 925-929.
11. Levi JA, Beith JM, Snyder RD, et al. Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer. Aust NZJ Med 1995, 25, 474-478.
12. Gurney H, Harnett P, Stuart-Harris R, et al. Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. Eur J Cancer 1996, 31A, 1773-1777.
13. Becher R, Kloke O, Hayungs J, et al. Epirubicin and ifosfamide in metastatic breast cancer. Semin Oncol 1996, 23(3 Suppl. 7), 28-33.
14. Valero V, Buzdar A, Walters R, et al. Phase II study of liposomal doxorubicin, 5-FU, cyclophosphamide in patients with metastatic breast cancer. Cancer Invest 1995, 13, 29-30.
15. Dhingra K, Frye D, Newman R, et al. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastic breast cancer. Clin Cancer Res 1995, 1, 691-697.
16. Herzig R, Lynch J, Christianson N, et al. Dose intensive chemotherapy with etoposide-cyclophosphamide without stem cell support for advanced breast cancer: a study of the North American Transplant Group. ProcASCO 1995, 14, Abst 323.
17. Mammoliti S, Merlini L, Caroti C, et al. Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin in elderly advanced breast cancer patients. Br Cancer Treat Res 1996, 37, 93-96.
18. Leonardi V, Meli M, Palmeri S, et al. A phase II trial of mitoxantrone plus cyclophosphamide and 5-FU in modulation with levo-folinate for advanced breast cancer patients. Chemotherapy 1995, 7, 160-166.
19. Alonso V, Santader C, Florian J, et al. Phase II trial of oral tegafur and folinic acid with mitoxantrone as first line regimen in patients with metastatic breast cancer. Tumori 1996, 82, 61-64.
20. Paves: L, Preti P, Da Prada G, et al. Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer. Anticancer Res 1995, 15, 495-501.
21. Dogliotti L, Berruti A, Buniva T, et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer. Results from a multicenter prospective randomized trial. J Clin Oncol 1996, 14, 1165-1172.
22. Cook AM, Chambers EJ, Rees GJG. Comparison of mitoxantrone and epirubicin in advanced breast cancer. PharmJ 1996, 257, 363-366.
23. Cocconi G, Anastasi P, Bella M, et al. Front-line CMF compared to a short chemotherapy with MVAC-like cisplatin containing combinations in metastatic breast carcinoma. Proc ASCO 1995, 14, Abst 136.
24. Alonso MC, et al. A phase III randomised trial of cyclophosphamide, mitoxantrone and 5-fluorouracil versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with metastatic breast cancer. Br Cancer Treat Res 1995, 34, 15-24.
25. Aisner J, Cirrincione C, Perloff M, et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast. A randomised phase III trial comparing CAP versus VATH versus VATH alternating with CMFVP: cancer and leukemia group B Study 8281. J Clin Oncol 1995, 13, 1443-1452.
26. Pierga JY, Jouve M, Asselain B, et al. Randomized trial comparing continuous infusion fluorouracil with weekly doxorubicin and cyclophosphamide to a monthly FAC regimen in metastatic breast carcinoma. Proc ASCO 1996, IS, Abs 133.
27. Colajori E, Ackland S, Anton A, et al. IV FEC with epirubicin 50mg/m2 dl, 8 prolongs time to progression with respect to iv CMF dl, 8 given at equimyelosuppressive doses as front line chemotherapy of metastatic breast cancer. Proc ASCO 1995, 14, Abs 156.
28. Pavesi L, et al. Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer. Anticancer Res 1995, 15, 495-501.
29. Pierga J-Y, Jouve M, Asselain B, et al. Randomised trial comparing continuous infusion fluorouracil with weekly doxorubicin and cyclophasphamide to a monthly FAC regimen in metastatic breast carcinoma. Proc ASCO 1996, 15, Abs 133.
30. Watanabe T, Fukuda H, Adachi I, et al. First line doxorubicin versus mitomycin C in patients with metastatic breast cancer. Proc ASCO 1996, 15, Abs 245.
31. Hausmaninger H, Lehnen M, Steger G, et al. Randomised phase II study of epirubicin-vindesine versus mitoxantronevindesine in metastatic breast cancer. Eur J Cancer 1995, 31A, 2169-2173.
32. Leong L, Doroshow JH, Lin S, et al. Phase II and molecular pharmacologie analysis of combination therapy for breast cancer with 5-fluorouracil, folinic acid, cisplatin and interferon alpha (IFN). Proc ASCO 1996, 15, 127.
33. Conzen SD, Kaufman 'PA, Arvizu C, et al. Phase II trial of tamoxifen, etoposide, mitoxantrone and cisplatin in patients with metastatic breast carcinoma. Cancer 1996, 78, 1906-1911.
34. Turrill M, Spicer DV, Kelley AS, et al. Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma. Cancer Invest 1995, 13, 160-164.
35. Closon MT, Verbeke L, Kains JP, et al. Combination chemotherapy with carboplatin, cyclophosphamide and fluorouracil in advanced breast cancer. Anticancer Res 1995, 15, 591-595.
36. Closon MT, Verbeke L, Kains JP, et al. Combination chemotherapy with carboplatin, cyclophosphamide and fluorouracil in advanced breast cancer. Anticancer Res 1995, 15, 591-595.
37. Zhang P, Zhou J, Feng F. The clinical eflicacy of CAC regimen in the treatment of advanced breast cancer. Chinese J Oncol 1995, 17, 365-367.
38. Raymond E, Palangie T, Jouve M, et al. Protracted continuous infusion of 5-FU in combination with doxorubicin, vincristine and oral cyclophosphamide in advanced breast cancer. Cancer Invest 1996, 14, 91-97.
39. Gurney H, Harnett P, 'Stuart-Harris R, Kefford R. Continuous infusion of vincristine, ifosfamide and epirubicin over six weeks in treatment resistant advanced breast cancer. Eur J Cancer 1995, 31A, 1773-1777.
40. Kiraz S, Baltali E, Guler N, et al. Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancer. J Chemother 1996, 8, 310-314.
41. Gurney H, Harnen P, Stuart-Harris R, et al. Continuous infusion of vincristine, ifosfomide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. Eur J Cancer 1995, 31, 1773-1777.
42. Colleoni M, Vicario G, Pancheri F, Sgarbossa G, Nelli P, Manente P. Oral levo-leucovorin and continuous fluorouracil infusion in metastatic breast cancer. ProcASCO 1996, 15, 130.
43. Lange OF, Jamitzky T. MRF (mitomycin, folinic acid, 5-FU) for metastatic breast cancer - a prospective pilot study. Eur J Cancer 1996, 32A(Suppl. 2), 54.
44. Colozza M, Gori S, Mosconi AM, et al. Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. Br Cancer Treat Res 1996, 38, 277-282.
45. Joseph G, Hamm, J, Morris K, et al. Phase II trial of 5-fluorouracil, folinic acid, and thiotepa in patients with advanced breast cancer. Am J Clin Oncol 1995, 18, 385-388.
46. Regazzoni S, Pesce G, Marini G, et al. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 1996, 7, 807-813.
47. Budd GT, Herzog P, Bukowski RM. Phase I/II trial of dipyridamole, 5-FU, leucovorin and mitoxantrone in metastatic breast cancer. Invest New Drugs 1994, 12, 283-287.
48. Joseph G, Hamm J, Morris K, et al. Phase II trial of 5-FU, folinic acid and N, Nl, Nll-triethylenethiophosphoramide (thiotepa) in patients with advanced breast cancer. Am J Clin Oncol 1995, 18, 385-388.
49. Leonardi V, Meli M, Palmeris, et al. A phase II trial of mitoxantrone plus cyclophosphamide and 5-FU in modulation with levo-folinate for advanced breast cancer patients. J Chemother 1995, 7, 160-166.
50. Wilke H, Klaassen U, Achterrath W, et al. Phase II study with a weekly 24-hour infusion of 5-FU plus high-dose folinic acid in intensively pretreated patients with metastatic breast cancer. Ann Oncol 1996, 7, 55-58.
51. Walters RS, Theriault RL, Booser DJ, et al Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous infusion 5-FU in metastatic breast cancer. J Immunother 1995, 18, 185-187.
52. Colozza M, Gori S, Mosconi AM, et al. Salvage chemotherapy in metastatic breast cancer. An experience with the combination of mitoxantrone, 5-FU, and L-leucovorin. Br Cancer Treat Res 1996, 38, 277-282.
53. Alonso V, Santander C, Florian J, et al. Phase II trial of oral tegafur and folinic acid with mitoxantrone as first line regimen in patients with metastatic breast cancer. Tumori 1996, 82, 61-64.
54. Sole LA, Ribas A, Bellmunt J, et al. High response rate with a CMF-based regimen in advanced and metastatic breast cancer. Preliminary results. Proc ASCO 1996, 15, Abs 125.
55. Remick SC, Chmura M, Bromberg C, et al. Concurrent 72 hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Am J Clin Oncol 1996, 19, 125-131.
56. Yokoe T, lino Y, Sugamata N, et al. Phase II trial of mitoxantrone, doxifluridine and medroxyprogesterone acetate as second line treatment for anthracycline resistant metastatic breast cancer. Anticancer Res 1995, 15, 2303-2305.
57. Paterson A, Darwin H, Temple C. Combination chemotherapy using methotrexate, mitoxantrone, and mitomycin C with continuous megestrol acetate in patients with metastatic carcinoma of the breast. Proc ASCO 1995, 14, Abs 195.
58. Raymond E, Palangie T, Jouve M, et al. Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine and oral cyclophosphamide in advanced breast cancer. Comment. Cancer Invest 1996, 14, 178-179.
59. Honkoop A, Hoekman K, Wagstaff J, et al. Neoadjuvant dose intensive chemotherapy with GM-CSF support followed by surgery and radiotherapy for locally advanced breast cancer. Proc ASCO 1995, 14, A215.
60. Bitran J, Samuels B, Marsik S, et al. A phase I study of ifosfamide and doxorubicin with recombinant human GCSF in stage IV breast cancer. Clin Cancer Res 1995, 1, 185-188.
61. Fountzillas G, Skarlos D, Katsohis C, et al. High-dose epirubicin and r-met-hu GCSF (Filigrastim) in the treatment of patients with advanced breast cancer. Pédiatrie Oncol 1995, 24, 23-28.
62. Lind MJ, Gumbrell L, Cantwell BM, et al. The use of granulocyte-colony stimulating factor to deliver four cycles of ifosfa-mide and epirubicin every 14 days in women with advanced or metastatic breast cancer. Br J Cancer 1995, 71, 610-613.
63. Piccart MJ, Bruning P, Wilddiers J. An EORTC pilot study of filagrastim (recombinant human granulocye colony stimulating factor) as support to a high dose intensive epiadriamycincyclophosphamide regimen in chemotherapy naïve patients with locally advanced or metastatic breast cancer. Ann Oncol 1995, 6, 673-677.
64. Scinto AF, Ferraresi V, Campioni N, et al. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer. Ann Oncol 1995, 6, 665-671.
65. Scinto AF, Cercato MC, Botti C, et cd. Phase II trial of high dose epirubicin and cyclophosphamide in advanced breast cancer. Eurjf Cancer 1994, 30A(9), 1285-1288.
66. Colucci G, Romito S, Gebbia V, et al. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with GCSF support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group. BrJ Cancer 1995, 72, 1245-1250.
67. laffaioli RV, Tortoriello A, Facchini G, et al Phase II study of high dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. Br Cancer Treat Res 1995, 35, 243-248.
68. Bissen D, Jodrell D, Harnett AN, et al. Phase I study of accelerated FEC with granulocyte colony-stimulating factor (lenograstim) support. BrJ Cancer 1995, 71, 1279-1282.
69. Fountzilas G, Skarlos D, Katsohis C, et al. High dose epirubicin and r-met-hu G-CSF (filigrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group Study. Med Pediatr Oncol 1995, 24, 23-28.
70. Colucci G, Romito S, Gebbia V, et al. Laevofolinic acid, 5-FU, cyclophosphamide, and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a Phase I/II study of the Southern Italy Oncology Group. BrJ Cancer 1995, 72, 1245-1250.
71. Astone A, Ferro A, Torino F, et al. High dose mitoxantrone cyclophosphamide with GM-CSF in first line chemotherapy of breast cancer. Eur J Cancer 1996, 32A(S2), 5-11.
72. Giotta F, Romito S, Gebbia V, et al. L-Folinic acid, fluorouracil, escalating doses of mitoxantrone, cyclophosphamide and G-CSF in advanced breast cancer patients. A phase I study. Eur J Cancer 1995, 31A(S5), 582.
73. Athanassiou A. Dose intensification by using human recombinant granulocyte-macrophage colony stimulating factor in advanced breast cancer patients. Eur J Gynecol Oncol 1996, 17, 411-413.
74. Kalaycioglu, et al High dose busulphan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral progenitor cell rescue for metastatic breast cancer. Am J Clin Oncol 1995, 18, 491-494.
75. Ayash LJ, Wheeler C, Fairclough D, et al Prognostic factors for prolonged progression free survival with high dose chemotherapy with autologous stem cell support for advanced breast cancer. J Clin Oncol 1995, 13, 2043-2049.
76. Patrone F, Ballestrero A, Ferranda F, et al. Four step high dose sequential chemotherapy with double haemopoietic progenitor cell rescue for metastatic breast cancer. J Clin Oncol 1995, 13, 840-846.
77. Spitzer TR, et al. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplantation 1995, 15, 537-542.
78. Gluck S, et al. High dose chemotherapy with autologous blood cell support in metastatic breast cancer. Proc EORTC 1996, 5-3.
79. Constantenia M, et al. Intensification chemotherapy with autologous peripheral blood progenitor cell support in patients with breast cancer: results of the transplantation procedure. Proc EORTC 1996, 5-19.
80. Erbal J, Miller K, Berkman E, et al. High dose chemotherapy with stem cell rescue following hormonal recruitment in women with stage IIIA-IV breast cancer in remission. Proc ASCO 1996, ISA, 146.
81. Mercier R, Reding D, Rushing D, et al. High dose chemotherapy with peripheral blood stem cell re-infusion dose escalation study of ifosfamide, VP-16 carboplatin in metastatic breast cancer. Proc ASCO 1996, 15A, 255.
82. Raftopoulos H, Vahdat L, Garnett TJ, et al. High dose chemotherapy with autologous stem cell rescue in patients with high risk and metastatic breast cancer: the Columbia University experience. Proc ASCO 1996, 15A, 1029.
83. Ferez L, Kopel S, Fan Y, et al. Feasibility of a novel regimen of high dose thiotepa, 1-phenylalanine, and carboplatin with autologous hematopoietic stem cell transplantation in breast cancer patients. Proc ASCO 1996, 15A, 1001.
84. deMagalhaes-Silverman M, et al. High dose cyclophosphamide, carboplatin and etoposide with autologous stem cell rescue in patients with breast cancer. Am J Clin Oncol 1996, 19, 169-173.
85. Saez R, et al. Long term survival after autologous bone marrow transplantation for metastatic breast carcinoma. Southern Med J 1995, 88, 320-326.
86. Fields K, Elfenbein GJ, Lazarus HM, et al. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 1995, 13, 323-332.
87. Mulder NH, et al. Long term results of induction and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer. Anticancer Res 1995, 15, 1565-1568.
88. Lioura B, et al. Intensive chemotherapy followed by autologous stem cell transplantation for metastatic breast cancer in complete remission. Proc ASCO 1995, 14, A86.
89. Peters WP, Jones RB, Vredenburgh J, et al. A large, prospective randomised trial of high-dose combination alkylating agents with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy. Proc ASCO 1996, 1996, ISA, 149.
90. Fay J, Jones S, Pineiro L, et al. The treatment of metastatic breast cancer with intensive carboplatin, thiotepa, cyclophosphamide, and autologous hemopoietic stem cell transplantation: A phase II trial of the North American Marrow Transplant Group. Proc ASCO 1996, 15A, 162.
91. Broun ER, Sridhara R, Sledge GW, et al. Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 1995, 13, 2050-2055.
92. Rodenhuis S, Westermann A, Holtkamp MJ, et al. Feasibility of multiple courses of high dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 1996, 14, 1473-1483.
93. Bitran JD, et al. Tandem high dose chemotherapy supported by hemopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplantation 1996, 17, 157-162.
94. Nabholtz JM, Gluck S, Crump M, et al. A pilot phase II study of FAC induction chemotherapy followed by two courses of high dose polychemotherapy supported with filgrastim mobilised peripheral blood progenitor cells in the first line treatment of metastatic breast cancer. Proc ASCO 1996, 15A, 254.
95. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995, 13, 2483-2489.
96. Rahman Z, Frye D, Buzdar A, Hortobagyi G. A retrospective analysis to evaluate the impact of selection process for high-dose chemotherapy (HDCT) on the outcome of patients (Pts) with metastatic breast cancer (MBC). Proc ASCO 1995, 14, Abs 78.
97. Colozza M, Gori S, Mosconi A, et al. Induction chemotherapy with cisplatin, doxorubicin and cyclophosphamide in a combined modality approach for locally advanced and inflammatory breast cancer. Long term results. Am J Clin Oncol 1996, 19, 10-17.
98. Lara FU, Zinser JW, Castanenda N, et al. Neoadjuvant chemotherapy with cisplatin, doxorubicin and cyclophosphamide (PAC) in stage II-HI breast cancer. ProcASCO, 1995, 14, Abs 179.
99. Colozza M, Gori S, Mosconi A, et al. Induction chemotherapy with cisplatin, doxorubicin and cyclophosphamide in a combined modality approach for locally advanced and inflammatory breast cancer. Long term results. Am J Clin Oncol 1996, 19, 10-17.
100. Tjulandin S, Stenina M, Toropov A, et al. Phase II study of FAC-PEM induction chemotherapy for locally advanced or metastatic breast cancer. Proc ASCO 1996, 15, Abs 194.
101. Restrepo J, Jimenez A, Vargas C, et al. Phase II trial of intensive induction chemotherapy with doxorubicin and ifosfamide in locally advanced breast cancer; preliminary report. Proc ASCO 1996, 15, Abs 190.
102. Machaivelli M, Romero A, Cuevas M, et al. Multidisciplinary treatments for locally advanced breast carcinoma. Proc ASCO 1995, 14, A188.
103. Purkalne G, Kudaba I. Response to neoadjuvant chemotherapy in locally advanced breast cancer. Bur J Cancer 1996, 32A(S2), 52.
104. Van der Wall E, Rutgers EJT, Holtkamp MJ, et al. Efficiency of up-front 5-FU, epidoxorubicin, cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high risk breast cancer patients. BrJ Cancer 1996, 73, 1080-1085.
105. Formenti SC, Uziely B, Dunnington C, et al. Continuous infusion 5-fluorouracil with radiation in locally advanced breast cancer: clinico-pathological and biological correlates. Proc ASCO 1995, 14A, 358.
106. Schwartz Breast conservation following induction chemotherapy for locally advanced carcinoma of the breast (stages II and III). Surg Oncol Clin North Am 1995, 4, 657-669.
107. Dreicer R, Jochimsen P, Mayr N, et al. Neoadjuvant VP-16, ifosfamide cisplatin plus filgrastim and hyperfractionated radiotherapy for inflammatory and locally advanced breast cancer. Proc ASCO 1995, 14, Abs 267.
108. Honkoop A, Hoekman K, Wagstaff J, et al. Neoadjuvant dose intensive chemotherapy with GM-CSF support followed by surgery and radiotherapy for locally advanced breast cancer. Proc ASCO 1995, 14, Abs 215.
109. Llombart Cussac A, Dohollou N, Rhor A, et al. Neoadjuvant high-dose FEC regimen with G-CSF (G) for large early breast cancer. EurJ Cancer 1996, 32A(S2), 34.
110. Smier B, Labedinsky C, Giangiacom G, et al. Intensive chemotherapy with 15 days interdose interval with G-CSF support in locally advanced breast cancer. Proc ASCO 1996, 15, Abs 188.
111. Artal A, Alons V, Gallego O, et al. FEC-75 plus G-CSF in locally advanced breast carcinoma. Proc EORTC 1996, Abstr 5-141.
112. Breier S, Lebedinsky C, Giangiacomo G, et al. Intensive chemotherapy with 15 days interdose interval with G-CSF support in locally advanced breast cancer. Proc ASCO 1996, 15, Abs 188.
113. Ayash LJ, et al. Prognostic factors for prolonged progression free survival with high dose chemotherapy with autologous stem cell support for advanced breast cancer. J Clin Oncol 1995, 13, 2043-2049.
114. Palangie T, Viens P, Texier V, et al. Repetetjve cycles of high dose cyclophosphamide and doxorubicin with G-CSF support mobilizes PBSC in inflammatory breast cancer. Proc ASCO 1995, 14, Abs 126.
115. Pautier P, Morvan F, Espie M, et al. High dose chemotherapy with ABMT as consolidation after standard dose chemotherapy and locoregional treatment for inflammatory breast cancer. Proc ASCO 1995, 14, Abs 117.
116. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995, 13, 424-429.
117. Van Praagh I, Leduc B, Feillel V, et al. Neoadjuvant VEM chemotherapy regimen for operable breast cancer: results of a cooperative study on 69 patients. ProcASCO 1995, 14, Abs 242.
118. Maltere P, Ris-Orangis, Martin M, et al. Neoadjuvant chemotherapy, fluorouracil, mitoxantrone and cyclophosphamide in operable locally advanced breast cancer. Proc ASCO 1995, 14, Abs 66.
119. Dohollou N, Floquet A, Pigneux A, et al. Neoadjuvant chemotherapy by VEC regimen in breast cancer. Preliminary results of a phase II trial. EurJ Cancer 1996, 32A(S2), 45.
120. Makris A, Powles TJ, Ashley SE, et al. A randomised trial of neoadjuvant chemoendocrine therapy in operable breast cancer. ProcASCO 1996, 15, Abs 51.
121. Scholl SM, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery. Proc ASCO 1995, 14, Abs 200.
122. Lara F, Zinser J, Castaneda N, et al. Neoadjuvant chemotherapy with cisplatm, doxorubicin and cyclophosphamide in stage II-III breast cancer. Proc ASCO 1995, 14, Abs 179.
123. Di Blasio B, Cocconi G, Boni C, et cd. Primary chemotherapy in operable breast carcinoma. A prospective randomised trial comparing CMF with an anthracycline-containing regimen. ProcASCO 1996, 15, Abs 169.
124. Bernado G, Plastina M, Bernado A, et al. Neoadjuvant chemotherapy (cyclophosphamide, epirubicin and fluorouracil) plus G-CSF for operable breast cancer. Proc ASCO 1995, 14, Abs 201.
125. Chollett Ph, Charrier S, Brain E, et cd. Neoadjuvant chemotherapy in breast cancer. High pathological response rate induced by intensive anthracyclin based regimen. Proc ASCO 1995, 14, Abs 218.
126. Graham M, Gonzalez P, Cance W, et al. Dose-intensive sequential adriamycin (A) and IV CMF (A>CMF) with G-CSF (G) support for stage II and III breast cancer (BrCa): A feasible and effective outpatient regimen. ProcASCO 1996, 15, Abs 137.
127. LJombart-Cussac A, Spielmann M, Rhor-Alvarado A, et al. High dose neoadjuvant cyclophosphamide, epirubicin, 5-fluorouracil and G-CSF for locally advanced breast cancer. Proc ASCO 1995, 14, Abs 189.
128. Dhingra K, Singletary E, Strom E, et cd. Randomised trial of G-CSF (Filgrastim)-supported dose-intense neoadjuvant chemotherapy in locally advanced breast cancer. Proc ASCO 1995, 14, Abs 76.
129. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995, 13, 1564-1571.
130. Winer EP, Chu L, Spicer DV. Oral vinorelbine is the treatment of advanced breast cancer. Semin Oncol 1995, 22m 72-78.
131. Bruno S, Puerto VL, Mickiewicz E, et al. Phase II trial of weekly iv vinorelbine as a single agent in first line advanced breast cancer chemotherapy. The Latin American Experience. Am J Clin Oncol 1995, 18, 392-396.
132. Höchster HS. Combined doxorubicin/vinorelbine (Navelbine) therapy in the treatment of advanced breast cancer. Semin Oncol 1995, 22, 55-60.
133. Frasci G, Comellia G, Salzano F, et al. Mitoxane plus vinorelbine with G-CSF support in advanced breast cancer patients. Br Cancer Treat Res 1995, 35, 147-156.
134. Nistico C, Garufi C, Ranuzzi M, et al. High activity in advanced breast cancer with the weekly combination of epirubicin, vinorelbine, and G-CSF. Proc ASCO 1996, Abs 228.
135. Leone B, Vallejo C, Romero A, Ferez J, et al. Ifosfamide (IPX) and vinorelbine (VNB) as first-line chemotherapy (FLC) for metastatic breast cancer (MBC): final results. Proc ASCO 1996, 15, Abs 74.
136. Hegg R, Costa MA, Cabral-Filho S, Correa M, et al. Phase II study of sequential navelbine (NVB) and doxorubicin (DX) for the treatment of metastatic breast cancer: preliminary results. Proc ASCO 1996, 15, Abs 65.
137. Baldini E, Tibaldi C, Da Prato M, Chiavacci A, et al. Epirubicin (E) + navelbine (NVB) as first line chemotherapy in advanced breast cancer (ABC) patients (PTS): a multicentric phase II study. Bur J Cancer 1996, 32A(S2), Abs 8-20.
138. Terzolie E, Nistico C, Ranuzzi M, et al. Weekly epirubicin plus vinorelbine in advanced breast cancer: preliminary results. Proc ASCO 1995, 14, Abstract 180.
139. Leone B, Vallejo C, Romero A, et al. Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. Proc ASCO 1996, 15, Abs 74.
140. Tterzoli E, Nistico C, Ranuzzi M, et al. Weekly epirubicin plus vinorelbine in advanced breast cancer: preliminary results. Proc ASCO 1995, 14, Abs 180.
141. Wendling JL, Nouyrigat P, Vallicioni D, et al. Cisplatinum (CDDP)-mitoxantrone (MTZ)-vinorelbine (VNR) as first line chemotherapy (CT) for metastatic breast cancer (MBC): a pilot study. Proc ASCO 1995, 14, Abs 266.
142. Leone B, Vallejo C, Romero A, Ferez J, et tu. Ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy (FLC) for metastatic breast cancer (MBC). Proc ASCO 1995, 14, Abs 187.
143. Vogel C, Hochster H, Blumenreich M, et cd. An USA multicenter phase II study of iv navelbine (NVB) and 5-fluorouracil (5FTJ) as first line treatment of patients with advanced breast cancer (ABC). Proc ASCO 1995, 14, Abs 62.
144. Caceres V, Alvarez A, Mickiewicz E, Ezcurdia L, et al. Vinorelbine (NVB) activity in heavily pretreated breast cancer (BC) patients (PTS). Proc ASCO 1996, IS, Abs 250.
145. Santoro A, Malorino L, Santoro M. Weekly vinorelbine as single agent for advanced breast cancer. EurJ Cancer 1996, 32A, 46.
146. Ranuzzi M, Nistico C, Garufi C, et al. vinorelbine in weekly schedule with G-CSF in patients with advanced breast cancer. Proc ASCO 1996, Abs 166.
147. Chevalier B, Bonneterre J, Hurteloup P, et al. Dose finding study of weekly oral vinorelbine in patients with advanced breast cancer: preliminary results. Eur J Cancer 1996, 32A, 47.
148. Kennedy M, Huelskamp, Clarke B, et al. Phase I evaluation of the incorporation of vinorelbine into dose-intense multi agent regimens for the treatment of metastatic breast cancer. Proc ASCO 1996, 15, Abs 90.
149. laffaioli R, Tortorriello A, Facchini G, et al. A phase II study of carboplatin and vinorelbine as second line treatment for advanced breast cancer. Br J Cancer 1995, 72, 1256-1258.
150. Wendling J, Nouyrigat P, Vallicioni D, et al. Cisplatin-mitoxantrone-vinorelbine as first line chemotherapy for metastatic breast cancer: a pilot study. Proc ASCO 1995, 14, Abs 266.
151. Kardinal CG, Cole JT, Gralla RJ, et al. Navelbine (vinorelbine and mitomycin C: combination therapy in advanced breast cancer. Proc ASCO 1995, 14, Abs 225.
152. Ray-Coquard I, Blay JY, Bachelot T, et al. Continuous iv infusion of vinorelbine (VNB) and bolus cisplatinum (CDDP) (civic regimen) an efficent regimen in hormone resistant metastatic breast cancer (MBC), after failure of anthracycline and/or paclitaxel. EurJ Cancer 1995, 31A(S77), A353.
153. Colleoni M, Nelli P, Gaion F, et al. Mitoxantrone, fluorouracil L-leucovorin, and vinorelbine in pretreated breast cancer. Oncology 1995, 52, 435-4s38.
154. Iaffaioli RV, Tortoriello A, Facchini G, et al. A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer. BrJ Cancer 1995, 72, 1256-1258.
155. Fabi A, Tonachella R, Savarese A, et al. A phase II trial of vinorelbine and thiotepa in metastatic breast cancer. Ann Oncol 1995, 6, 187-189.
156. Casella FG, Frasci G, Cornella G, et al. Mitoxantrone plus vinorelbine with granulocyte colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study. Br Cancer Treat Res 1995, 35, 147-156.
157. Colleoni M, Nelli P, Gaion F, et al. Mitoxantrone, fluorouracil plus L-leucovorin, and vinorelbine in pretreated advanced breast cancer. Oncology 1995, 52, 435-438.
158. Kornek GV, Haider K, Kwasny W, et al. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. Br J Cancer 1996, 74, 1668-1673.
159. Norris B, Pritchard K, James K, et al. A phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer. A National Cancer Institute of Canada study. Proc ASCO 1996, 15, Abs 98.
160. Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995, 13, 2567-2574.
161. Theriault RL, Walters RS, Holmes FA, et al. A phase II study of CI-973[SP-4-3(R)]-1, 1-cyclobutane-dicarboxylato(2-)] (2-methyl-1, 4-butanediamine-Af, Af) platinum in patients with refractory advanced breast cancer. Cancer Chemother Pharmacol 1996, 38, 289-291.
162. Atienza DM, Vogel CL, Trock B, Swain SM. Phase II study of oral etoposide for patients with advanced breast cancer. Cancer 1995, 76, 2485-2490.
163. Bontenbal M, Planting AST, Verweij J, et al. Second-line chemotherapy with long term low-dose oral etoposide in patients with advanced breast cancer. Br Cancer Treat Res, 1995, 34, 185-189.
164. Neskovic Konstantinovic ZB, Bosnjak SM, Radulovic SS, et al. Daily oral etoposide in metastatic breast cancer. Anticancer Drugs 1996, 7, 543-547.
165. Atienza D, Vogel CL, Trock B, et al. Phase II study of oral etoposide for patients with advanced breast cancer. Cancer 1995, 76, 2485-2490.
166. Bontenbal M, Planting AS, Verweij J, et al. Second line chemotherapy with long term low dose oral etoposide in patients with advanced breast cancer. Br Cancer Treat Res 1995, 34, 185-189.
167. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995, 13, 2731-2736.
168. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995, 13, 2731-2736.
169. Blackstein M, Vogel C, Ambinder R, et al. Phase II study of gemcitabine in patients with metastatic breast cancer. Proc ASCO 1996, 15, Abs 135.
170. Perez-Manga G, Lluch A, Garcia-Conde J, et al. Early phase II study of gemcitabine in combination with doxorubicin in advanced breast cancer. Proc ASCO 1995, 14, Abs 89.
171. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995, 13, 2731-2736.
172. Prove A, Becquart D, Joosen E, et al. Oral idarubicin chemodierapy in elderly advanced breast cancer patients progressing after hormonal therapy: preliminary results. Proc ASCO 1996, 15, Abs 177.
173. Marshall E, Mackay J, Ranson M, et al. Oral regimen, idarubicin plus cyclophosphamide in advanced breast cancer patients. Preliminary results of a phase I-II trial. Proc ASCO 1995, 14, Abs 264.
174. Campos D, Puricelli G, Matwiejuk M, et cd. Antitumour activity of oral idarubicin in postmenopausal patients with metastatic breast cancer. Proc ASCO 1995, 14, Abs 262.
175. Ingle JN, Krook JE, Mailliard JA, et al. Evaluation of ifosfamide plus mesna as first line chemotherapy in women with metastatic breast cancer. Am J Clin Oncol 1995, 18, 498-501.
176. Ranson M, O'Byrne K, Carmichael J, et cd. Phase II dose finding trial of DOX-SL in the treatment of advanced breast cancer. Proc ASCO 1996, 15, Abs 161.
177. Repetto L, Simoni C, Venturino A, et al. Mitoxantrone in elderly women with advanced breast cancer: a phase II study. Anticancer Res 1995, 15, 2297-2300.
178. Ravdin PM, Green S, Doroshow JH, et al. Phase II trial of piroxantrone in metastatic breast cancer. A Southwest Oncology Group Study. Invest New Drugs 1994, 12, 333-336.
179. Smith I, Jones A, Spielmann M, et al. A phase II study in advanced breast cancer: Tomudex, a novel direct and specific thymidylate synthase inhibitor. Br J Cancer 1996, 74, 479-481.
180. Smith I, Jones A, Spielmann M, et al. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer 1996, 74, 479-481.
181. Chang AY, Garrow G, Boros L, Asbury R, Pandya K, Keng P., Clinical and laboratory studies of topotecan in breast cancer. Proc ASCO 1995, 14, Abs 118.
182. Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL. Phase I study of topotecan and cisplatin in patients with advanced solid tumours: a cancer and leukemia group B study. J Clin Oncol 1994, 12, 2743-2750.
183. Uziely B, Jeffers S, Isaacson R, et al. Liposomal doxorubicin antitumour activity and unique toxicities during 2 complementary phase I studies. J Clin Oncol 1995, 13, 1777-1785.